Table 2. Bleeding events in COVID-19 patients with thrombosis.
| Gender | Age (y) | Type(s) of bleed | WHO bleeding grade | Platelets at bleed (K/µL) | Bleed before or after thrombosis | AC before bleed | AC after bleed | ICU at the time of bleed | Fatal bleed | Hospital mortality | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 66 | Hemorrhagic stroke | Grade 4 | 265 | Same time | Prophylactic (UFH) | Therapeutic (UFH) | Yes | No | Alive | Transformation from embolic stroke |
| M | 62 | Hemithorax | Grade 4 | 55 | After | Therapeutic (argatroban) | Therapeutic (bivalirudin) | Yes | No | Alive | ECMO |
| M | 47 | Nasal, oropharngeal | Grade 4 | 143 | After | Therapeutic (argatroban) | Therapeutic (argatroban) | Yes | No | Alive | ECMO |
| M | 55 | Hemorrhagic stroke | Grade 4 | 240 | After | Therapeutic (LMWH) | Therapeutic (LMWH) | Yes | No | Deceased | |
| F | 44 | Nasal, oropharngeal, rectal, vaginal | Grade 4 | 264 | After | Therapeutic (LMWH) | None | Yes | No | Alive | Recurrent Bleed |
| M | 46 | Nasal and hemorrhagic stroke | Grade 4 | 154 | After | Therapeutic (LMWH), tPA | None | Yes | No | Deceased | |
| F | 58 | Hemoptysis | Grade 2 | 13 | After | None | None | No | No | Alive | Current AML |
| F | 45 | Nasal | Grade 2 | 102 | After | Therapeutic (bivalirudin) | Therapeutic (bivalirudin) | Yes | No | Alive | ECMO |
| M | 48 | HD catheter bleed | Grade 3 | 147 | After | Prophylactic (UFH) | None | Yes | No | Deceased | |
| M | 77 | Oropharyngeal and hemorrhagic stroke | Grade 4 | 117 | Same time | Therapeutic (LMWH) | Therapeutic (LMWH) | No | No | Alive | DIC on admission |
| M | 72 | Nasal | Grade 2 | 322 | Before | None | Prophylactic (LMWH) and tPA | No | No | Deceased | |
| F | 63 | Hemorrhagic stroke | Grade 4 | 186 | After | Therapeutic (LMWH) | Therapeutic (bivalirudin) | No | No | Alive | |
| M | 45 | Oropharyngeal | Grade 2 | 51 | Before | Therapeutic (LMWH) | Prophylactic (LMWH) | Yes | No | Deceased | |
| M | 32 | GI | Grade 2 | 288 | After | Therapeutic (LMWH), warfarin | Therapeutic (UFH) | Yes | No | Alive | |
| F | 60 | GI | Grade 2 | 308 | Before | Prophylactic (LMWH) | Therapeutic (apixaban) | Yes | No | Alive | |
| M | 51 | Hemorrhagic stroke | Grade 4 | 224 | Same time | Therapeutic (LMWH) | None | Yes | No | Deceased | |
| F | 88 | Hemorrhagic stroke | Grade 4 | 167 | Same time | None | None | No | No | Alive | Discharge to hospice |
Abbreviations: AC, anticoagulation; COVID-19, novel coronavirus disease 2019; DIC, disseminated intravascular coagulation; ECMO, extracorporeal membrane oxygenation; F, female; GI, gastrointestinal; ICU, intensive care unit; LMWH, low molecular weight heparin; M, male; UFH, unfractionated heparin; WHO, World Health Organization; AML, acute myeloid leukaemia; HO, hemodialysis; TPA, tissue plasminogen activator.